

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005 DELAWARE

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY

BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,

BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES

AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS. BY BENEFICIARY CHARACTERISTIC

TABLE D.12, USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY

BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74 SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL

ELIGIBLE BENEFICIARIES

TABLE ND.2 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY $^{a,\ b}$ NONDUAL BENEFICIARIES, DELAWARE, 2005

		1	Number of			DELAWARE	_, 2003	Nı	umber of B	enefit Mon	ths	
Beneficiary						Other/						Other/
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	103,704	176	9,716	46,816	46,965	31	1,020,449	1,839	109,713	420,260	488,353	284
Age												
5 and younger	22,394	0	643	1	21,750	0	229,442	0	7,141	6	222,295	0
6-14	20,380	0	2,227	1	18,152	0	219,965	0	25,637	9	194,319	0
15-20	11,867	0	1,406	3,403	7,057	1	118,567	0	16,133	30,742	71,686	6
21-44	36,279	3	2,406	33,860	5	5	333,367	7	27,144	306,137	46	33
45-64	12,408	1	3,018	9,363	1	25	115,372	3	33,513	81,604	7	245
65-74	219	58	16	145	0	0	2,126	647	145	1,334	0	0
75-84	101	67	0	34	0	0	1,047	712	0	335	0	0
85 and older	56	47	0	9	0	0	563	470	0	93	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	65,073	127	4,867	36,082	23,966	31	634,484	1,332	55,087	328,410	249,371	284
Male	38,631	49	4,849	10,734	22,999	0	385,965	507	54,626	91,850	238,982	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Race												
White	46,596	63	4,642	23,455	18,411	25	448,687	629	52,054	208,370	187,411	223
African American	44,260	77	4,209	19,178	20,791	5	444,926	820	47,906	174,220	221,922	58
Other/unknown	12,848	36	865	4,183	7,763	1	126,836	390	9,753	37,670	79,020	3
Use of Nursing Facilities ^c												
Entire year	115	36	79	0	0	0	1,248	376	872	0	0	0
Part year	93	14	74	5	0	0	889	104	728	57	0	0
None	103,496	126	9,563	46,811	46,965	31	1,018,312	1,359	108,113	420,203	488,353	284
Maintenance Assistance Statu	s											
Cash	52,881	116	8,343	15,622	28,800	0	550,374	1,322	94,432	154,956	299,664	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty-related	3,608	7	7	313	3,250	31	31,285	31	27	1,867	29,076	284
Other/unknown	47,215	53	1,366	30,881	14,915	0	438,790	486	15,254	263,437	159,613	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	3,172	1	1	3,095	75	0	23,826	1	1	23,310	514	0
FFS part year, with Rx claims	3,860	5	30	3,746	77	2	15,558	23	89	15,112	322	12
FFS part year, no Rx claims	1,344	3	6	1,269	65	1	6,828	9	26	6,483	308	2

Source: Data for this table are from the MAX 2005 file for Delaware, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3 ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, DELAWARE, 2005

	Percentage with	Mean Number			Mean \$, All Medicaid	Rx \$ as a Percentage of All Medicaid	Number of
Characteristics	at Least One Rx	of Rx	Mean Rx \$	\$ per Rx	FFS \$c	FFS \$d	Beneficiaries
All	95.2	12.3	\$796	\$65	\$917	86.9	103,704
Age							
5 and younger	98.1	6.0	308	52	308	100.0	22,394
6-14	99.0	8.3	602	73	602	100.0	20,380
15-20	96.7	8.7	564	65	699	80.8	11,867
21-44	91.0	13.3	818	62	1,077	76.0	36,279
45-64	94.6	30.1	2,121	70	2,242	94.6	12,408
65-74	99.1	31.6	1,907	60	1,908	99.9	219
75-84	99.0	34.5	2,001	58	2,040	98.1	101
85 and older	100.0	36.5	1,573	43	1,573	100.0	56
Unknown	0.0	0.0	0	0	0	0.0	0
Basis of Eligibilitye							
Aged	97.7	39.6	2,053	52	2,121	96.8	176
Disabled	99.6	33.0	2,963	90	2,990	99.1	9,716
Adults	91.2	13.8	784	57	1,037	75.6	46,816
Children	98.3	6.4	354	56	362	97.9	46,965
Unknown	96.8	23.1	2,999	130	3,131	95.8	31
Gender							
Female	93.0	12.8	761	59	952	80.0	65,073
Male	98.9	11.3	856	76	858	99.8	38,631
Unknown	0.0	0.0	0	0	0	0.0	0
Race							
White	95.7	15.3	1,014	66	1,141	88.9	46,596
African American	94.9	10.1	640	64	762	84.0	44,260
Other/unknown	94.7	8.8	543	62	634	85.7	12,848
Use of Nursing Facil	ities ^f						
Entire year	100.0	87.0	4,832	56	4,832	100.0	115
Part year	100.0	62.3	3,975	64	4,779	83.2	93
None	95.2	12.2	789	65	909	86.8	103,496
Maintenance Assista	ince Status						
Cash	98.5	12.7	845	66	900	93.9	52,881
Medically needy	0.0	0.0	0	0	0	0.0	0
Poverty related	97.8	5.6	310	56	382	81.3	3,608
Other/unknown	91.4	12.3	779	64	976	79.8	47,215

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving fost care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence. Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{A, b}
NONDUAL BENEFICIARIES, DELAWARE, 2005

			. <u>-</u>		Num	ber of Rx, P	ercentage w	ith:		_	Numbe	er
Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$c	None		More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10		Beneficiaries	Benefit Months
All	1.2	\$81	86.9	4.8	69.8	10.4	10.3	3.6	1.0	\$93	103,704	1,020,449
Age												
5 and younger	0.6	30	100.0	1.9	90.3	5.7	1.9	0.2	0.0	30	22,394	229,442
6-14	0.8	56	100.0	1.0	84.3	8.4	5.6	0.7	0.0	56	20,380	219,965
15-20	0.9	57	80.8	3.3	79.2	9.4	6.5	1.2	0.4	70	11,867	118,567
21-44	1.4	89	76.0	9.0	59.6	12.8	12.9	4.2	1.5	117	36,279	333,367
45-64	3.2	228	94.6	5.4	31.4	16.2	28.8	14.6	3.6	241	12,408	115,372
65-74	3.3	196	99.9	0.9	33.3	15.1	31.5	16.9	2.3	197	219	2,126
75-84	3.3	193	98.1	1.0	32.7	16.8	33.7	12.9	3.0	197	101	1,047
85 and older	3.6	157	100.0	0.0	28.6	12.5	39.3	19.6	0.0	157	56	563
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Basis of Eligibility	_/ e											
Aged	3.8	197	96.8	2.3	21.6	21.0	34.1	18.8	2.3	203	176	1,839
Disabled	2.9	262	99.1	0.4	41.7	15.5	25.8	13.5	3.1	265	9,716	109,713
Adults	1.5	87	75.6	8.8	57.0	13.3	14.5	4.9	1.5	116	46,816	420,260
Children	0.6	34	97.9	1.7	88.6	6.5	2.9	0.2	0.0	35	46,965	488,353
Unknown	2.5	327	95.8	3.2	48.4	22.6	12.9	6.5	6.5	342	31	284
Gender												
Female	1.3	78	80.0	7.0	66.6	10.4	10.6	4.1	1.4	98	65,073	634,484
Male	1.1	86	99.8	1.1	75.4	10.5	9.9	2.8	0.3	86	38,631	385,965
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Race												
White	1.6	105	88.9	4.3	63.0	12.2	13.7	5.3	1.5	119	46,596	448,687
African American	1.0	64	84.0	5.1	74.7	9.3	8.0	2.3	0.7	76	44,260	444,926
Other/unknown	0.9	55	85.7	5.3	78.2	7.8	6.3	2.0	0.5	64	12,848	126,836
Use of Nursing Fa	cilities ^f											
Entire year	8.0	445	100.0	0.0	8.7	2.6	23.5	46.1	19.1	445	115	1,248
Part year	6.5	416	83.2	0.0	14.0	7.5	31.2	26.9	20.4	500	93	889
None	1.2	80	86.8	4.8	70.0	10.4	10.3	3.5	1.0	92	103,496	1,018,312
Maintenance Assi	stance Status	:										
Cash	1.2	81	93.9	1.5	75.4	9.7	9.1	3.4	0.8	87	52,881	550,374
Medically needy	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Poverty related	0.6	36	81.3	2.2	86.7	7.4	3.3	0.3	0.2	44	3,608	31,285
Other/unknown	1.3	84	79.8	8.6	62.3	11.4	12.3	4.1	1.3	105	47,215	438,790

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would be the plans.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{A, b, c}

NONDUAL BENEFICIARIES, DELAWARE, 2005

		All Rx		Patented	d Brand Drugs	d-Name	Off-Pater	nt Bran Drugs	id-Name	Gen	eric D	rugs
Beneficiary	Number			Number			Number			Number		
Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	1.2	\$81	\$65	0.5	\$60	\$122	0.0	\$4	\$83	0.7	\$17	\$24
Age												
5 and younger	0.6	30	52	0.2	23	117	0.0	1	58	0.4	7	18
6-14	0.8	56	73	0.4	47	112	0.0	2	83	0.3	7	22
15-20	0.9	57	65	0.4	44	115	0.0	3	64	0.4	9	22
21-44	1.4	89	62	0.5	63	123	0.1	5	77	0.9	22	25
45-64	3.2	228	70	1.3	164	130	0.1	12	108	1.9	52	28
65-74	3.3	196	60	1.3	150	114	0.1	4	52	1.8	42	23
75-84	3.3	193	58	1.4	150	105	0.1	4	40	1.8	39	22
85 and older	3.6	157	43	1.3	111	83	0.1	5	46	2.2	41	19
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	(
Basis of Eligibility	rd											
Aged	3.8	197	52	1.5	148	100	0.1	5	43	2.2	44	20
Disabled	2.9	262	90	1.3	207	165	0.1	11	101	1.6	44	28
Adults	1.5	87	57	0.6	60	108	0.1	5	82	0.9	23	24
Children	0.6	34	56	0.3	26	100	0.0	1	65	0.3	6	20
Unknown	2.5	327	130	1.2	284	232	0.0	1	124	1.3	42	33
Gender												
Female	1.3	78	59	0.5	56	112	0.1	4	75	0.8	18	24
Male	1.1	86	76	0.5	66	138	0.0	4	102	0.6	16	25
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	(
Race												
White	1.6	105	66	0.6	77	120	0.1	5	89	0.9	24	26
African American	1.0	64	64	0.4	48	125	0.0	3	78	0.6	12	2
Other/unknown	0.9	55	62	0.3	42	120	0.0	2	66	0.5	11	2
Use of Nursing Fa	cilitiese											
Entire year	8.0	445	56	2.7	324	120	0.6	24	44	4.8	97	20
Part year	6.5	416	64	2.2	299	133	0.3	16	51	4.0	101	20
None	1.2	80	65	0.5	59	122	0.0	4	84	0.7	17	24
Maintenance Assi	stance Sta	tus										
Cash	1.2	81	66	0.5	60	125	0.0	4	82	0.7	17	2
Medically needy	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	(
Poverty related	0.6	36	56	0.3	27	108	0.0	1	64	0.4	7	19
Other/unknown	1.3	84	64	0.5	62	118	0.0	4	85	0.7	18	24

a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Delaware, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}

NONDUAL BENEFICIARIES, DELAWARE, 2005

			x per Ber ong User		\$ per	Benefit N Us	Month Amers	iong		\$ per	·Rx					Userse	
Therapeutic Category	F Total	atented Brand- Name	Brand-	Seneric		atented Brand- Name		eneric	F Total	atented Brand- Name		Seneric	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.2	0.1	0.0	0.1	\$20	\$14	\$2	\$3	\$80	\$190	\$85	\$24	160,055	\$12,828,966	62,401	60.2	647,491
Biologicals	0.3	0.3	0.0	0.0	300	287	13	0	983	957	7,316	34	1,717	1,687,964	595	0.6	5,631
Antineoplastic Agents	0.4	0.1	0.0	0.3	129	112	0	17	310	797	255	63	2,612	810,762	609	0.6	6,262
Endocrine/Metabolic Drugs	0.4	0.2	0.0	0.2	22	15	2	6	55	93	65	25	121,014	6,628,638	29,095	28.1	296,832
Cardiovascular Agents	0.9	0.4	0.0	0.5	44	34	0	9	47	83	50	17	142,083	6,622,942	15,257	14.7	152,077
Respiratory Agents	0.4	0.2	0.0	0.2	22	18	1	3	56	86	61	17	194,207	10,830,326	46,762	45.1	488,885
Gastrointestinal Agents	0.4	0.2	0.0	0.2	26	21	0	4	72	136	61	21	49,248	3,537,921	13,283	12.8	136,761
Genitourinary Agents	0.2	0.1	0.0	0.1	11	7	1	2	52	72	58	26	15,289	797,485	7,118	6.9	73,533
CNS Drugs	0.8	0.4	0.0	0.4	59	50	0	9	76	129	100	24	179,888	13,742,635	23,179	22.4	232,537
Stimulants/Anti-obesity/Anorexia	0.7	0.5	0.0	0.1	57	52	0	4	87	96	108	42	43,626	3,801,577	6,139	5.9	66,755
Miscellaneous Psychological/ Neurological Agents	0.3	0.3	0.0	0.1	154	148	0	6	461	547	105	100	1,569	723,971	476		4,704
Analgesics and Anesthetics	0.5	0.0	0.0	0.4	19	5	2	12	42	174	153	28	171,078	7,113,761	37,140		375,780
Neuromuscular Agents	0.5	0.2	0.0	0.3	42	27	2	12	78	142	107	38	78,138	6,063,282	14,352	13.8	145,951
Nutritional Products	0.2	0.1	0.0	0.1	5	2	0	2	22	36	24	16	16,580	369,387	7,455	7.2	76,118
Hematological Agents	0.5	0.2	0.0	0.2	108	103	1	4	239	491	30	17	13,421	3,204,078	2,944	2.8	29,724
Topical Products	0.2	0.1	0.0	0.1	9	6	0	3	43	82	54	22	78,152	3,355,640	35,154	33.9	371,381
Miscellaneous Products	0.2	0.1	0.0	0.0	16	13	2	2	106	129	307	37	4,129	437,458	2,498	2.4	26,740
Unknown Therapeutic Category	0.1	0.0	0.0	0.0	7	0	0	0	47	0	0	0	482	22,540	316	0.3	3,401
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	1,273,288	82,579,333	n.a.	n.a.	n.a.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum

of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Delaware, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c} NONDUAL BENEFICIARIES, DELAWARE, 2005

	-		Users		An	nong Usei	'S
Top 10 Drug Groups	Total Medicaid Rx	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months		\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$6,655,078	7,065	6.8	74,085	0.5	\$188	\$90
ANTIVIRAL	6,621,069	3,456	3.3	36,221	0.4	464	183
ANTIASTHMATIC	5,606,085	32,560	31.4	345,435	0.2	66	16
ANTIDEPRESSANTS	4,815,986	18,806	18.1	188,963	0.4	62	25
ANTICONVULSANT	4,442,857	7,677	7.4	80,284	0.5	103	55
ANALGESICS - Narcotic	4,003,295	35,716	34.4	366,132	0.3	40	11
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	3,494,146	6,713	6.5	73,574	0.5	87	47
ANTIHYPERLIPIDEMIC	2,695,816	6,059	5.8	62,162	0.4	97	43
ULCER DRUGS	2,542,763	10,587	10.2	109,582	0.3	78	23
ANTIDIABETIC	2,495,829	6,511	6.3	64,506	0.5	71	39
Total	43,372,924	135,150		1,400,944	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Delaware, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$

⁼ Medicaid reimbursement.

TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, DELAWARE, 2005

	All Top 10	Drug Groups		ANTI	PSYCHOTIC	S			,	ANTIVIRAL		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users			Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean lumber of Rx per I Benefit Month	Mean Rx \$ per Benefit Month
All	490,685	\$43,372,924	7,065	6.8	74,085	0.5	\$90	3,456	3.3	36,221	0.4	\$183
Female												
All Females	298,791	24,227,534	3,937	6.1	41,240	0.4	78	2,280	3.5	24,036	0.3	134
Female, Disabled												
All Ages	85,845	8,937,688	1,359	27.9	15,579	0.6	111	594	12.2	6,771	0.5	247
5 and younger	1,299	102,022	1	0.4	12	0.3	1	6	2.2	72	0.7	93
6-14	6,481	686,360	107	15.9	1,219	0.5	97	24	3.6	288	0.6	248
15-20	4,981	508,966	124	21.5	1,454	0.5	101	17	2.9	192	0.4	127
45-64	24,747	2,728,472	559	39.6	6,355	0.5	101	263	18.7	2,955	0.4	202
45-64	48,083	4,892,935	565	29.4	6,503	0.6	125	284	14.8	3,264	0.6	298
65-74	254	18,933	3	37.5	36	0.7	88	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	212,946	15,289,846	2,578	4.3	25,661	0.4	59	1,686	2.8	17,265	0.3	90
5 and younger	9,782	622,342	8	0.1	85	0.3	50	44	0.4	484	0.1	9
6-14	19,122	1,481,089	233	2.6	2,595	0.5	84	79	0.9	855	0.2	31
15-20	15,359	975,059	310	4.4	3,255	0.4	66	166	2.4	1,693	0.2	30
21-44	108,621	7,339,981	1,545	5.7	15,074	0.3	51	1,125	4.2	11,595	0.3	80
45-64	57,355	4,701,061	455	7.4	4,386	0.4	65	267	4.3	2,588	0.4	210
65-74	1,339	80,577	4	2.8	39	1.3	65	3	2.1	26	0.2	11
75-84	867	60,126	10	14.9	90	0.7	100	0	0.0	0	0.0	0
85 and older	501	29,611	13	29.5	137	0.6	79	2	4.5	24	0.1	4
Male												
All Males	191,894	19,145,390	3,128	8.1	32,845	0.5	104	1,176	3.0	12,185	0.5	278
Male, Disabled												
All Ages	67,351	8,588,954	1,382	28.5	15,748	0.6	126	599	12.4	6,540	0.6	343
5 and younger	2,262	198,391	17	4.6	198	0.4	64	8	2.2	96	0.6	89
6-14	17,706	1,777,547	449	28.9	5,121	0.6	105	21	1.4	247	0.4	95
15-20	8,013	901,705	243	29.3	2,809	0.6	123	10	1.2	120	0.5	152
21-44	16,523	2,629,887	418	42.0	4,802	0.7	141	235	23.6	2,548	0.7	385
45-64	22,651	3,057,059	255	23.3	2,818	0.7	144	323	29.6	3,505	0.6	343
65-74	196	24,365	0	0.0	0	0.0	0	2	25.0	24	0.8	518
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, DELAWARE, 2005

	All Top 10	Drug Groups		ANTI	PSYCHOTIC	S			A	ANTIVIRAL		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month
Male, Other Eligibles												
All Ages	124,543	10,556,436	1,746	5.2	17,097	0.4	85	577	1.7	5,645	0.4	203
5 and younger	13,313	870,372	44	0.4	492	0.4	75	35	0.3	370	0.1	4
6-14	34,399	2,979,372	498	5.5	5,437	0.5	96	78	0.9	878	0.3	61
15-20	10,749	948,689	249	7.2	2,652	0.5	99	43	1.2	444	0.2	50
21-44	36,956	3,102,684	679	10.0	5,995	0.4	71	251	3.7	2,326	0.4	235
45-64	27,930	2,550,840	262	8.1	2,376	0.4	77	164	5.1	1,555	0.5	328
65-74	647	64,303	3	5.0	28	0.5	118	3	5.0	36	0.8	324
75-84	402	32,495	7	20.6	79	0.5	107	1	2.9	12	0.1	5
85 and older	147	7,681	4	33.3	38	0.7	58	2	16.7	24	0.1	11
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Delaware, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, DELAWARE, 2005

ANTIASTHMATIC ANTIDEPRESSANTS ANTICONVULSANT Mean Mean Mean Number of Number Number of Number Number of Number Users Benefit Mean Benefit Mean Mean of Rx Users of Rx Users Benefit of Rx Months per Rx \$ per as % Months per Rx \$ per per Rx \$ per as % as % Months Among Benefit Benefit Among Benefit Number of of All Benefit Number of of All Number of of All Benefit Among Benefit **Beneficiary Characteristics** Month Users Benes Users Month Month Users Benes Users Month Month Users Benes Users Month 80,284 ΑII 32.560 31.4 345,435 0.2 \$16 18,806 18.1 188,963 0.4 \$26 7,677 7.4 0.5 \$55 Female All Females 18,109 27.8 191,772 0.2 16 13,899 21.4 140,495 0.4 26 4,906 7.5 51,369 0.5 51 Female, Disabled 30,457 17,479 All Ages 2.659 54.6 0.3 25 2.588 53.2 29.406 0.5 30 1.522 31.3 0.7 73 18 12 72 221 81.0 2,498 0.3 1 0.4 8 0.3 31 11.4 361 0.6 5 and younger 25 23 6-14 420 62.4 4,901 0.3 75 11.1 868 0.5 149 22.1 1,751 8.0 93 1,810 15-20 209 36.2 2,460 0.3 16 158 27.3 0.4 19 141 24.4 1,638 0.7 92 18 29 575 21-44 616 43.7 6,988 0.3 985 69.9 11,194 40.8 6,584 78 0.5 0.7 32 32 45-64 1,180 61.3 13,472 0.4 1,364 70.9 15,481 0.5 623 32.4 7,109 0.6 60 65-74 13 162.5 138 27 62.5 45 0.3 19 3 37.5 36 102 0.4 5 0.5 75-84 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 85 and older 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 Female, Other Eligibles All Ages 15,450 25.7 161,315 0.2 14 11,311 18.8 111,089 0.4 25 3,384 5.6 33,890 0.4 40 5 and younger 4,156 39.0 44,570 0.2 12 3 0.0 36 0.3 13 37 0.3 423 0.4 38 6-14 3,388 37.4 37,249 0.2 14 293 3.2 3,146 0.4 19 130 1.4 1,375 0.5 49 15-20 1.424 20.3 14,699 0.2 11 875 12.5 9.000 0.3 18 250 3.6 2.590 0.4 45 21-44 4,714 17.4 47,213 0.2 7,517 27.8 74,047 24 2,188 8.1 21,957 36 14 0.4 0.4 45-64 1,716 27.9 17,034 0.3 24 2,564 41.6 24,254 0.5 32 755 12.3 7,324 48 0.5 65-74 28 19.6 289 0.4 24 29 20.3 311 0.5 24 12 8.4 122 0.6 39 75-84 15 22.4 154 28 20.9 130 44 7 10.4 52 0.4 14 0.7 0.6 24 47 85 and older 9 20.5 107 0.3 9 16 36.4 165 0.7 24 5 11.4 0.5 23 Male All Males 14,451 37.4 153,663 0.2 17 4,907 12.7 48,468 0.4 24 2,771 7.2 28,915 0.6 63 Male, Disabled All Ages 2,181 45.0 24,845 0.3 23 1,295 26.7 14,611 0.5 27 1,229 25.3 14,072 0.7 80 352 95.1 3,987 0.3 26 42 0.3 50 13.5 565 68 5 and younger 4 1.1 4 0.6 6-14 860 55.3 9,957 0.3 19 204 13.1 2,355 0.5 20 305 19.6 3,514 0.7 87 15-20 305 36.8 3,530 0.3 19 172 20.8 2,007 0.5 23 177 21.4 2,081 0.7 79 23.9 27 27 388 21-44 238 2.686 0.3 433 43.5 4.930 0.5 39.0 4.455 0.8 87 32 478 31 45-64 418 38.2 4,633 0.5 43.7 5,242 0.5 306 28.0 3,424 0.7 66 65-74 8 100.0 52 0.6 36 4 50.0 35 0.4 17 3 37.5 33 0.9 38 75-84 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0 0 0.0 0 0.0 0 0 0 0.0 0 0.0 85 and older 0.0 0 0.0

TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, DELAWARE, 2005

		ANTIA	ASTHMATIC				ANTIDI	EPRESSAN	TS			ANTIC	ONVULSAN	1T	
				Mean					Mean					Mean	
			Number of		Maan			Number of		Maan			Number of		Maan
		Users as %	Benefit Months	of Rx	Mean Rx \$ per		Users as %	Benefit Months	of Rx	Mean Rx \$ per		Users as %	Benefit Months	of Rx	Mean Rx \$ per
	Number of	of All	Among	Benefit		Number of	of All	Among			Number of	of All	Among	Benefit	
Beneficiary Characteristics	Users	Benes	Users				Benes	Users		Month			Users		
Male, Other Eligibles															
All Ages	12,270	36.3	128,818	0.2	15	3,612	10.7	33,857	0.4	24	1,542	4.6	14,843	0.5	47
5 and younger	5,280	47.6	56,167	0.2	12	0	0.0	0	0.0	0	38	0.3	425	0.3	39
6-14	4,345	47.8	47,015	0.2	16	324	3.6	3,572	0.4	20	197	2.2	2,154	0.6	69
15-20	954	27.6	10,000	0.2	13	355	10.3	3,642	0.4	24	132	3.8	1,390	0.5	65
21-44	1,037	15.2	9,419	0.3	22	1,963	28.9	17,653	0.4	23	758	11.1	6,906	0.4	40
45-64	629	19.5	5,923	0.4	26	952	29.4	8,817	0.4	26	406	12.6	3,850	0.5	42
65-74	11	18.3	126	0.7	74	8	13.3	84	0.5	24	4	6.7	42	0.9	28
75-84	14	41.2	168	0.3	22	7	20.6	73	0.6	41	6	17.6	64	1.0	42
85 and older	0	0.0	0	0.0	0	3	25.0	16	0.8	55	1	8.3	12	1.0	8
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Delaware, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

${\it TABLE~ND.7C}\\ {\it MEDICAID~PHARMACY~BENEFIT~USE~AND~REIMBURSEMENT~FOR~SIXTH~TO~EIGHTH~TOP~DRUG~GROUPS~SEPARATELY,}$

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, DELAWARE, 2005

		ANALG	SESICS - Nard	cotic				TI-OBESITY/		ANTS		ANTIH	YPERLIPIDE	EMIC	
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users			Number of Users	Users as % of All Benes	Number of Benefit Months Among Users		Mean Rx \$ per Benefit Month
All	35,716	34.4	366,132	0.3	\$11	6,713	6.5	73,574	0.5	\$48	6,059	5.8	62,162	0.4	\$43
Female															
All Females	25,650	39.4	266,146	0.3	9	1,989	3.1	21,711	0.5	44	3,808	5.9	39,470	0.4	43
Female, Disable	d														
All Ages	3,274	67.3	37,532	0.4	18	399	8.2	4,657	0.6	51	1,107	22.7	12,657	0.5	46
5 and younger	31	11.4	368	0.1	1	5	1.8	53	0.3	21	0	0.0	0	0.0	0
6-14	51	7.6	600	0.1	1	240	35.7	2,798	0.6	51	1	0.1	11	0.1	1
15-20	169	29.2	1,941	0.1	2	124	21.5	1,458	0.5	48	2	0.3	24	0.2	16
21-44	1,177	83.5	13,522	0.3	17	23	1.6	264	0.6	70	179	12.7	2,061	0.4	38
45-64	1,841	95.6	21,050	0.4	21	7	0.4	84	0.6	51	920	47.8	10,510	0.5	48
65-74	5	62.5	51	0.3	7	0	0.0	0	0.0	0	5	62.5	51	0.6	66
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other El	ligibles														
All Ages	22,376	37.2	228,614	0.2	8	1,590	2.6	17,054	0.5	43	2,701	4.5	26,813	0.4	41
5 and younger	249	2.3	2,839	0.1	1	54	0.5	597	0.3	29	2	0.0	24	0.1	4
6-14	607	6.7	6,740	0.1	1	1,016	11.2	11,024	0.5	44	4	0.0	33	0.2	! 14
15-20	2,401	34.3	24,766	0.1	2	321	4.6	3,390	0.5	41	24	0.3	228	0.3	28
21-44	15,435	57.0	157,675	0.2	7	182	0.7	1,899	0.5	40	894	3.3	9,013	0.3	32
45-64	3,578	58.1	35,454	0.3	17	17	0.3	144	0.5	46	1,680	27.3	16,497	0.5	46
65-74	48	33.6	481	0.3	6	0	0.0	0	0.0	0	55	38.5	551	0.5	48
75-84	35	52.2	405	0.3	7	0	0.0	0	0.0	0	35	52.2	397	0.5	5 51
85 and older	23	52.3	254	0.2	3	0	0.0	0	0.0	0	7	15.9	70	0.7	67
Male															
All Males	10,066	26.1	99,986	0.3	15	4,724	12.2	51,863	0.6	49	2,251	5.8	22,692	0.5	44
Male, Disabled															
All Ages	1,654	34.1	18,572	0.4	27	1,398	28.8	16,155	0.6	50	627	12.9	7,078	0.5	48
5 and younger	31	8.4	349	0.1	1	33	8.9	383	0.3	24	0	0.0	0	0.0	0
6-14	144	9.3	1,688	0.1	1	993	63.9	11,462	0.6	50	2	0.1	24	0.3	3 7
15-20	164	19.8	1,918	0.1	1	345	41.7	4,005	0.5	51	3	0.4	36	0.6	52
21-44	487	48.9	5,440	0.4	29	23	2.3	258	0.7	57	139	14.0	1,622	0.6	49
45-64	823	75.3	9,135	0.5	37	4	0.4	47	0.5	41	480	43.9	5,380	0.5	48
65-74	5	62.5	42	0.9	76	0	0.0	0	0.0	0	3	37.5	16	0.8	73
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

TABLE ND.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, DELAWARE, 2005

		ANALO	GESICS - Nard	cotic		STIMULA	NTS/AN	TI-OBESITY/	ANOREXIA	ANTS		ANTIF	IYPERLIPIDE	MIC	
		Users	Number of Benefit N	Mean	Mean		Users	Number of	Mean lumber of	Mean		Users	Number of	Mean Jumber of	Mean
		as %			Rx \$ per		as %	Months		Rx \$ per		as %			Rx \$ per
Beneficiary	Number of	of All	Among	Benefit	Benefit		of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	Benefit
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
Male, Other Elig	ibles														
All Ages	8,412	24.9	81,414	0.3	13	3,326	9.8	35,708	0.5	48	1,624	4.8	15,614	0.4	42
5 and younger	365	3.3	4,001	0.1	1	174	1.6	1,950	0.4	29	2	0.0	24	0.1	19
6-14	600	6.6	6,612	0.1	1	2,530	27.8	27,395	0.6	49	10	0.1	113	0.2	18
15-20	941	27.2	9,796	0.1	2	538	15.6	5,583	0.5	51	18	0.5	205	0.3	21
21-44	4,460	65.6	41,513	0.3	14	73	1.1	663	0.5	46	587	8.6	5,812	0.4	36
45-64	2,023	62.6	19,236	0.4	21	11	0.3	117	0.6	74	963	29.8	9,009	0.5	46
65-74	11	18.3	122	0.4	37	0	0.0	0	0.0	0	32	53.3	307	0.6	70
75-84	5	14.7	60	0.1	2	0	0.0	0	0.0	0	9	26.5	108	0.6	55
85 and older	7	58.3	74	0.3	4	0	0.0	0	0.0	0	3	25.0	36	0.8	66
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Delaware, released by CMS in 10/2008. This table was produced on 04/23/2009.

Bene(s) = Deneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.7D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, DELAWARE, 2005

ULCER DRUGS ANTIDIABETIC Number of Mean Number of Mean Users Benefit Number of Mean Users Benefit Number of Mean Rx per Rx \$ per as % as % Months Months Rx per Rx \$ per Beneficiary Number of of All Among Benefit Benefit Number of of All Among Benefit Benefit Number of Number of Characteristics Benes Users Beneficiaries Benefit Months Users Users Month Month Benes Users Month Month ΑII 10.587 10.2 109.582 0.3 \$23 6.511 6.3 64,506 0.5 \$39 103,704 1.020.449 **Female** All Females 7,236 11.1 75,454 0.3 22 4,238 6.5 42,811 0.5 38 65,073 634,484 Female, Disabled All Ages 1,597 32.8 18,431 0.4 31 1,200 24.7 13,633 0.6 41 4,867 55,087 77 26 273 5 and younger 28.2 850 0.4 2 0.7 24 0.1 12 3,023 99 38 6-14 14.7 1,167 0.4 8 1.2 96 0.5 62 673 7,777 15-20 81 14.0 949 0.4 31 23 4.0 260 0.5 43 578 6.638 427 25 1,410 21-44 30.3 4,925 0.3 214 15.2 2,402 0.5 33 15,988 908 45-64 47.2 10,486 0.4 33 947 49.2 10,791 0.6 42 1,925 21,580 5 65-74 62.5 54 0.6 14 6 75.0 60 0.9 52 8 81 0 75-84 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0 85 and older 0 0.0 0 0.0 0 0 0.0 0.0 0 0 0 Female, Other Eligibles All Ages 5,639 9.4 57,023 0.3 19 3,038 5.0 29,178 0.5 37 60,206 579,397 415 3.9 3,888 0.2 11 7 0.1 71 0.5 42 10,655 109,327 5 and younger 254 2.8 2,827 0.2 15 67 0.7 682 0.6 66 9,066 97,486 6-14 15-20 422 6.0 4,387 0.2 10 105 1.5 996 0.5 38 7,003 67,353 4.8 21-44 2,993 11.1 30,679 0.2 17 1,293 12,387 0.5 33 27,071 248,567 45-64 1,460 23.7 14,307 0.4 31 1,478 24.0 14,124 0.6 38 6,157 54,124 65-74 44 30.8 410 0.3 22 58 40.6 606 0.7 34 143 1,407 75-84 32 47.8 355 0.5 25 23 34.3 0.6 36 67 228 699 85 and older 19 43.2 170 0.4 20 7 15.9 84 0.9 46 44 434 Male 3,351 All Males 8.7 34,128 0.3 25 2,273 21,695 0.6 40 38,631 385,965 5.9 Male. Disabled All Ages 870 17.9 34 602 43 4,849 9,855 0.4 12.4 6,743 0.6 54,626 90 24.3 991 0.4 26 4 47 0.5 31 370 5 and younger 1.1 4,118 6-14 141 9.1 1,681 0.4 40 32 2.1 362 0.7 72 1,554 17,860 15-20 72 8.7 846 0.3 29 25 3.0 291 0.9 104 828 9,495 21-44 185 18.6 2.090 0.5 37 121 12.1 1,361 39 996 0.6 11,156 45-64 378 34.6 4,215 0.4 33 416 38.1 4,640 0.6 38 1,093 11,933 65-74 50.0 32 0.7 35 50.0 42 0.7 65 8 64 75-84 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0 0 0.0 0 0 0 85 and older 0 0.0 0 0.0 0 0 0.0

TABLE ND.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c

NONDUAL BENEFICIARIES, DELAWARE, 2005

		UL	CER DRUGS				ΙA	NTIDIABETIC				
			Number of	Mean				Number of	Mean			
		Users			Mean		Users		lumber of	Mean		
		as %			Rx \$ per		as %			Rx \$ per		
Beneficiary	Number of	of All	- 3	Benefit		Number of	of All	Among	Benefit		Number of	Number of
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Beneficiaries B	enefit Months
Male, Other Elig	ibles											
All Ages	2,481	7.3	24,273	0.3	22	1,671	4.9	14,952	0.6	39	33,782	331,339
5 and younger	493	4.4	4,681	0.2	12	4	0.0	44	0.7	46	11,096	112,974
6-14	229	2.5	2,477	0.2	21	37	0.4	379	0.5	49	9,087	96,842
15-20	151	4.4	1,627	0.2	12	50	1.4	485	0.7	70	3,458	35,081
21-44	926	13.6	8,912	0.3	23	608	8.9	5,515	0.6	39	6,802	57,656
45-64	662	20.5	6,363	0.4	31	932	28.8	8,151	0.5	37	3,233	27,735
65-74	12	20.0	122	0.5	32	23	38.3	192	0.7	36	60	574
75-84	5	14.7	60	0.4	19	15	44.1	162	0.6	46	34	348
85 and older	3	25.0	31	0.6	35	2	16.7	24	1.0	19	12	129
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2005 file for Delaware, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan. com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = Deneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC^{a, b}

NONDUAL BENEFICIARIES, DELAWARE, 2005

D		North and Donas Daniell	Normalia and All Maran Normalia an	Benefit Months Among All-
Beneficiary	Dy C nor Donofit Month	•	Number of All-Year Nursing	Year Nursing Facility
Characteristics	Rx \$ per Benefit Month	Month		Residents
All	\$445	8.0	115	1,248
Age				
0-64	532	9.0	76	846
65-74	375	7.9	8	86
75-84	329	5.5	10	99
85 and older	189	5.2	21	217
Unknown	0	0.0	0	0
Gender				
Female	466	8.6	70	752
Male	414	7.1	45	496
Unknown	0	0.0	0	0
Race				
White	423	7.2	49	517
African American	439	8.7	58	635
Other/unknown	604	7.9	8	96
Basis of Eligibility	:			
Aged	238	5.7	36	376
Disabled	534	9.0	79	872
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2005 file for Delaware, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2005 Medicaid enrollment. A total of 93 beneficiaries who were in

nursing facilities for part of their enrollment and their 889 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORYA, b, c, d, e NONDUAL BENEFICIARIES, DELAWARE, 2005

Number of Rx per Benefit \$ per Benefit Month Among

Month Among Users Users \$ per Rx Users

Users

Therapeutic Category	P	atented Brand- Name	Off- Patent Brand- Name G	Generic		atented Brand- Name	Off- Patent Brand- Name G	Seneric	P	atented Brand- Name	Off- Patent Brand- Name G		Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.6	0.3	0.0	0.3	\$71	\$62	\$3	\$7	\$125	\$245	\$74	\$24	539	\$67,550	85	73.9	946
Biologicals	0.1	0.0	0.0	0.1	2	0	0	2	28	0	0	28	4	112	4	3.5	45
Antineoplastic Agents	0.4	0.1	0.0	0.2	98	69	0	29	272	591	0	120	31	8,436	8	7.0	86
Endocrine/Metabolic Drugs	1.1	0.5	0.1	0.5	45	36	2	6	41	79	19	12	547	22,218	45	39.1	499
Cardiovascular Agents	1.8	0.5	0.0	1.3	55	36	0	19	30	68	33	15	1,586	47,806	80	69.6	872
Respiratory Agents	1.3	0.5	0.0	0.8	53	40	1	11	39	84	58	13	827	32,626	54	47.0	620
Gastrointestinal Agents	1.4	0.4	0.2	0.9	47	31	4	11	33	82	25	13	1,274	42,264	81	70.4	904
Genitourinary Agents	0.7	0.3	0.0	0.3	28	22	0	5	40	66	65	15	214	8,636	29	25.2	313
CNS Drugs	1.6	0.8	0.0	0.8	111	93	0	18	67	115	65	21	1,462	98,601	83	72.2	889
Stimulants/Anti-obesity/Anorexia	0.4	0.0	0.1	0.3	10	0	4	7	24	0	42	20	5	122	1	0.9	12
Miscellaneous Psychological/ Neurological Agents	0.8	0.8	0.0	0.0	181	181	0	0	241	241	0	0	63	15,205	7	6.1	84
Analgesics and Anesthetics	1.2	0.1	0.1	1.0	50	11	12	28	41	130	88	28	789	32,492	61	53.0	650
Neuromuscular Agents	1.7	0.5	0.3	1.0	129	75	14	40	74	164	53	39	1,235	91,314	63	54.8	708
Nutritional Products	0.5	0.0	0.0	0.5	8	1	0	7	14	31	20	14	191	2,737	32	27.8	351
Hematological Agents	1.3	0.5	0.2	0.6	117	108	3	6	88	208	14	10	706	61,961	49	42.6	531
Topical Products	0.7	0.3	0.0	0.3	29	21	2	7	45	66	48	23	515	23,223	71	61.7	790
Miscellaneous Products	0.2	0.1	0.0	0.1	5	4	0	1	30	58	0	12	8	236	4	3.5	48
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	3	0	0	0	11	0	0	0	10	108	3	2.6	31
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	10,006	555,647	n.a.	n.a.	n.a.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were in nursing facilities for part of their enrollment and their 889 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In Delaware, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicaire & Medicaird Services; CNS = Central Nervous System; MAX = Medicaird Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaird erimbursement.

TABLE ND.10 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP-10 DRUG GROUPa, b, c, d NONDUAL BENEFICIARIES, DELAWARE, 2005

			Users				Among Users
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Monthspe	Number of Rx er Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTICONVULSANT	\$71,214	81	70.4	928	1.1	\$73	\$77
ANTIPSYCHOTICS	59,269	53	46.1	609	0.7	148	97
ANTIVIRAL	48,464	24	20.9	288	0.5	356	168
ANTIDEPRESSANTS	34,169	76	66.1	819	0.8	53	42
ULCER DRUGS	32,834	81	70.4	915	0.7	49	36
ANALGESICS - Narcotic	25,501	76	66.1	824	0.8	41	31
ANTICOAGULANTS	23,034	26	22.6	273	1.3	66	84
ANTIASTHMATIC	22,485	67	58.3	765	0.8	38	29
HEMATOPOIETIC AGENTS	22,439	22	19.1	259	0.8	112	87
ANTIHYPERLIPIDEMIC	16,625	25	21.7	294	0.8	74	57
Total	356,034	531		5,974	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Delaware, released by CMS in 10/2008. This table was produced on 04/23/2009.

Medicaid reimbursement.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were

a. Table ND. 10 includes the betterioralises presented by Cen L of Table 1, those with resident in Table 1, those with residen

group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); CMS = Centers for Medicaire & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$=

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d NONDUAL BENEFICIARIES, DELAWARE, 2005

	All Top 10 Di	ug Groups		ANTICON	NVULSANT				ANTIPS	YCHOTICS		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents		Mean Number of Rx	
All	4,804	\$356,034	81	70.4	928	1.1	\$77	53	46.1	609	0.7	\$97
Female												
All Females	3,064	217,806	43	61.4	481	1.1	83	40	57.1	466	0.6	105
Female, Disabled												
All Ages	2,490	185,630	39	92.9	446	1.1	87	26	61.9	302	0.6	108
64 or younger	2,406	177,253	37	92.5	422	1.2	85	23	57.5	266	0.6	111
65-74	84	8,377	2	100.0	24	0.6	117	3	150.0	36	0.7	88
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	574	32,176	4	14.3	35	0.7	32	14	50.0	164	0.7	99
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	79	2,406	1	33.3	12	0.8	50	0	0.0	0	0.0	0
75-84	164	13,154	0	0.0	0	0.0	0	5	83.3	60	0.6	110
85 and older	331	16,616	3	15.8	23	0.7	22	9	47.4	104	0.7	92
Male												
All Males	1,740	138,228	38	84.4	447	1.0	70	13	28.9	143	0.7	74
Male, Disabled												
All Ages	1,556	128,897	36	97.3	423	1.0	73	9	24.3	95	0.7	70
64 or younger	1,548	127,752	36	100.0	423	1.0	73	9	25.0	95	0.7	70
65-74	8	1,145	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Eligibles												
All Ages	184	9,331	2	25.0	24	1.0	21	4	50.0	48	0.8	82
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	82	4,065	1	50.0	12	1.0	34	0	0.0	0	0.0	0
75-84	40	2,946	0	0.0	0	0.0	0	1	25.0	12	1.0	159
85 and older	62	2,320	1	50.0	12	1.0	8	3	150.0	36	0.8	56
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were

a. Table No. Those includes a fee brieficial estephesement by Cell E of Table 1, those with resident ministring facilities for part of their enrollment and their 889 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state. d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters

Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007). Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, DELAWARE, 2005

		AN	TIVIRAL				ANTIDEF	PRESSANTS	3			ULCE	R DRUGS		
Beneficiary Characteristics	Number of Users	Year Nursing Facility	Number of Benefit Months Among N	Mean Number of Rx		Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users			Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	
All	24	20.9	288	0.5		76	66.1	819			81	70.4	915		
Female															
All Females	9	12.9	108	0.4	106	51	72.9	534	0.8	44	54	77.1	613	0.8	36
Female, Disable	d														
All Ages	8	19.0	96	0.5	119	37	88.1	377	0.9	50	40	95.2	455	0.8	40
64 or younger	8	20.0	96	0.5	119	36	90.0	365	0.9	51	38	95.0	431	0.8	41
65-74	0	0.0	0	0.0	0	1	50.0	12	0.2	12	2	100.0	24	1.0	16
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
Female, Other E	ligibles														
All Ages	1	3.6	12	0.1	2	14	50.0	157	0.8	29	14	50.0	158	0.6	26
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
65-74	0	0.0	0	0.0	0	2	66.7	24	0.8	22	1	33.3	12	0.3	31
75-84	0	0.0	0	0.0	0	2	33.3	24	1.1	78	4	66.7	48	0.9	38
85 and older	1	5.3	12	0.1	2	10	52.6	109	0.7	20	9	47.4	98	0.5	19
Male															
All Males	15	33.3	180	0.5	206	25	55.6	285	0.7	38	27	60.0	302	0.7	35
Male, Disabled															
All Ages	13	35.1	156	0.6	237	22	59.5	252	0.6	39	25	67.6	278	0.7	37
64 or younger	13	36.1	156	0.6	237	22	61.1	252	0.6	39	24	66.7	276	0.7	38
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	100.0	2	0.5	1
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
Male, Other Elig	ibles														
All Ages	2	25.0	24	0.1	4	3	37.5	33	1.2	31	2	25.0	24	0.8	
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
65-74	0	0.0	0	0.0	0	1	50.0	12	1.0	7	1	50.0	12	0.8	
75-84	1	25.0	12	0.1	5	2	50.0	21	1.2	45	0	0.0	0	0.0	C
85 and older	1	50.0	12	0.1	2	0	0.0	0	0.0	0	1	50.0	12		7
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C

Source: Data for this table are from the MAX 2005 file for Delaware, released by CMS in 10/2008. This table was produced on 04/23/2009.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were in nursing facilities for part of their enrollment and their 889 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d NONDUAL BENEFICIARIES, DELAWARE, 2005

		ANALGES	SICS - Narco	ic			ANTICO	AGULANTS				ANTIAS	STHMATIC		
Beneficiary Characteristics	Number of Users	Users as % of All- Year Nursing Facility Residents				Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users			Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	
All	76		824				22.6	273				58.3	765		
Female															
All Females	55	78.6	603	0.7	28	14	20.0	138	1.4	78	40	57.1	461	0.8	3:
Female, Disable	d														
All Ages	35	83.3	373	0.9	43	12	28.6	114	1.4	91	29	69.0	330	1.0	38
64 or younger	35	87.5	373	0.9	43	11	27.5	102	1.6	92	26	65.0	294	1.1	4:
65-74	0	0.0	0	0.0	0	1	50.0	12	0.3	81	3	150.0	36	0.2	: :
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0) (
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0) (
Female, Other E	ligibles														
All Ages	20	71.4	230	0.3	5	2	7.1	24	1.5	19	11	39.3	131	0.4	- 17
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0) (
65-74	4	133.3	48	0.5	12	1	33.3	12	1.8	22	0	0.0	0	0.0) (
75-84	2	33.3	24	0.2	1	0	0.0	0	0.0	0	5	83.3	60	0.5	33
85 and older	14	73.7	158	0.2	3	1	5.3	12	1.2	16	6	31.6	71	0.3	
Male															
All Males	21	46.7	221	0.9	38	12	26.7	135	1.1	91	27	60.0	304	0.7	2
Male, Disabled															
All Ages	17	45.9	173	1.0	46	11	29.7	123	1.2	99	24	64.9	268	0.7	17
64 or younger	16	44.4	171	1.0	41	11	30.6	123	1.2	99	22	61.1	264	0.7	1
65-74	1	100.0	2	2.5	513	0	0.0	0	0.0	0	2	200.0	4	0.5	30
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
Male, Other Elig	ibles														
All Ages	4	50.0	48	0.7	8	1	12.5	12	0.2	4	3	37.5	36	0.8	88
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0) (
65-74	2	100.0	24	0.9	12	1	50.0	12	0.2	4	2	100.0	24	1.1	13
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	25.0	12	0.1	:
85 and older	2	100.0	24	0.5	5	0	0.0	0	0.0	0	0	0.0	0	0.0) (
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0) (

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were in nursing facilities for part of their enrollment and their 889 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each

group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}

NONDUAL BENEFICIARIES, DELAWARE, 2005

HEMATOPOIETIC AGENTS

ANTIHYPERLIPIDEMIC

Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months	Mean Number of Rx		All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	22	19.1	259	0.8	\$87	25	21.7	294	0.8	\$57	115	1,248
Female												
All Females	15	21.4	175	0.8	110	15	21.4	174	0.8	59	70	752
Female, Disable	ed											
All Ages	12	28.6	139	0.8	137	11	26.2	126	0.8	62	42	460
64 or younger	12	30.0	139	0.8	137	10	25.0	114	0.8	62	40	436
65-74	0	0.0	0	0.0	0	1	50.0	12	0.7	71	2	24
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Female, Other I	Eligibles											
All Ages	3	10.7	36	0.8	4	4	14.3	48	0.8	48	28	292
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	0	0.0	0	0.0	0	1	33.3	12	0.1	6	3	36
75-84	1	16.7	12	1.0	5	1	16.7	12	1.1	70	6	63
85 and older	2	10.5	24	0.8	4	2	10.5	24	1.0	59	19	193
Male												
All Males	7	15.6	84	0.7	39	10	22.2	120	0.7	54	45	496
Male, Disabled												
All Ages	7	18.9	84	0.7	39	10	27.0	120	0.7	54	37	412
64 or younger	7	19.4	84	0.7	39	10	27.8	120	0.7	54	36	410
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	2
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Male, Other Elig	gibles											
All Ages	0	0.0	0	0.0	0	0	0.0	0	0.0	0	8	84
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	24
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	4	36
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	24
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were in nursing facilities for part of their enrollment and their 889 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{9,b} DELAWARE, 2005

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx	\$ per	Total Part D Excluded Rx \$		Part D Excluded Rx \$ as a ercentage of All Nondual Rx \$	Total Number of Beneficiaries
All	40,047	38.6	1.3	134,145	\$22	\$2,244,222	\$17	2.7	103,704
Age									
5 and younger	9,942	44.4	0.9	19,127	15	330,030	17	4.8	22,394
6-14	6,113	30.0	0.6	11,959	12	246,179	21	2.0	20,380
15-20	3,385	28.5	0.6	7,432	12	142,368	19	2.1	11,867
21-44	13,814	38.1	1.5	52,643	23	847,008	16	2.9	36,279
45-64	6,589	53.1	3.4	41,709	53	663,494	16	2.5	12,408
65-74	118	53.9	3.3	713	37	8,005	11	1.9	219
75-84	58	57.4	3.9	389	39	3,921	10	1.9	101
85 and older	28	50.0	3.1	173	57	3,217	19	3.7	56
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Basis of Eligibility	c								
Aged	107	60.8	4.4	776	50	8,757	11	2.4	176
Disabled	5,041	51.9	3.7	35,856	59	575,277	16	2.0	9,716
Adults	17,924	38.3	1.4	66,664	24	1,121,385	17	3.1	46,816
Children	16,963	36.1	0.7	30,763	11	537,642	17	3.2	46,965
Unknown	12	38.7	2.8	86	37	1,161	14	1.2	31
Gender									
Female	25,935	39.9	1.4	91,868	23	1,467,419	16	3.0	65,073
Male	14,112	36.5	1.1	42,277	20	776,803	18	2.3	38,631
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Race									
White	18,453	39.6	1.6	75,430	28	1,286,199	17	2.7	46,596
African American	15,946	36.0	1.0	44,628	17	737,198	17	2.6	44,260
Other/unknown	5,648	44.0	1.1	14,087	17	220,825	16	3.2	12,848
Use of Nursing Fa	cilities ^d								
Entire year	70	60.9	6.3	726	108	12,452	17	2.2	115
Part year	69	74.2	6.4	597	84	7,796	13	2.1	93
None	39,908	38.6	1.3	132,822	21	2,223,974	17	2.7	103,496
Maintenance Assi	stance Status								
Cash	21,798	41.2	1.4	75,430	23	1,206,580	16	2.7	52,881
Medically needy	0	0.0	0.0	0	0	0	0	0.0	0
Poverty related	1,321	36.6	0.7	2,454	12	42,020	17	3.8	3,608
Other/unknown	16,928	35.9	1.2	56,261	21	995,622	18	2.7	47,215

a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b} DELAWARE, 2005

Beneficiary Characteristics	Number Rx per	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of
All	0.1	\$2	\$17	\$0	\$1	1,020,449
Age		*-	• • •	**	**	1,1-1,111
5 and younger	0.1	1	17	0	0	229,442
6-14	0.1	1	21	0	0	219,965
15-20	0.1	1	19	0	0	118,567
21-44	0.2	3	16	0	1	333,367
45-64	0.4	6	16	0	2	115,372
65-74	0.3	4	11	0	1	2,126
75-84	0.4	4	10	0	1	1,047
85 and older	0.3	6	19	0	1	563
Unknown	0.0	0	0	0	0	0
Basis of Eligibility ^c						
Aged	0.4	5	11	0	1	1,839
Disabled	0.3	5	16	0	2	109,713
Adults	0.2	3	17	0	1	420,260
Children	0.1	1	17	0	0	488,353
Unknown	0.3	4	14	0	2	284
Gender						
Female	0.1	2	16	0	1	634,484
Male	0.1	2	18	0	0	385,965
Unknown	0.0	0	0	0	0	0
Race						
White	0.2	3	17	0	1	448,687
African American	0.1	2	17	0	0	444,926
Other/unknown	0.1	2	16	0	0	126,836
Use of Nursing Facil	ities ^d					
Entire year	0.6	10	17	1	4	1,248
Part year	0.7	9	13	0	4	889
None	0.1	2	17	0	1	1,018,312
Maintenance Assista	nce Status					
Cash	0.1	2	16	0	1	550,374
Medically needy	0.0	0	0	0	0	0
Poverty related	0.1	1	17	0	0	31,285
Other/unknown	0.1	2	18	0	1	438,790

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include they barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE ND.13

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,C}
DELAWARE, 2005

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx
All	51,266	\$44	\$2,244,222	100.0	134,145	\$17	100.0
Anorexia or weight loss/gain	0	0	0	0.0	0	0	0.0
Fertility drugs	0	0	0	0.0	0	0	0.0
Drugs for cosmetic purposes	72	16	1,129	0.1	96	12	0.1
Cough and cold medications	21,308	48	1,012,361	45.1	37,577	27	28.0
Vitamins and minerals	3,105	41	127,774	5.7	8,394	15	6.3
Non-prescription drugs	17,079	22	372,536	16.6	41,951	9	31.3
Barbiturates	222	54	12,038	0.5	1,770	7	1.3
Benzodiazepines	8,325	69	578,080	25.8	41,424	14	30.9
Other Part D Excl Rx Drugs	1,155	121	140,304	6.3	2,933	48	2.2

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2005. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

APPENDIX TABLE A.1 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b} MONDLIAL BENEFICIADIES DELAWARE 2005

	NONDUAL BENEFICIARIES, DELAWARE, 2005 Number of Beneficiaries Number of Benefit Months											
Beneficiary Characteristics	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown
All	150,441	208	11,669	63,168	75,348	48	1,395,499	2,098	127,934	554,733	710,365	369
Age												
5 and younger	32,899	0	793	2	32,104	0	302,693	0	8,400	15	294,278	0
6-14	33,769	0	2,760	2	31,007	0	335,112	0	30,843	20	304,249	0
15-20	19,139	0	1,874	5,035	12,228	2	177,207	0	20,591	44,849	111,759	8
21-44	48,672	3	2,874	45,769	8	18	438,043	27	31,640	406,217	72	87
45-64	15,504	1	3,352	12,122	1	28	138,141	7	36,315	101,538	7	274
65-74	266	68	16	182	0	0	2,436	720	145	1,571	0	0
75-84	127	82	0	45	0	0	1,233	826	0	407	0	0
85 and older	65	54	0	11	0	0	634	518	0	116	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	87,541	148	5,546	43,841	37,958	48	833,905	1,487	61,294	411,778	358,977	369
Male	62,900	60	6,123	19,327	37,390	0	561,594	611	66,640	142,955	351,388	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Race												
White	63,603	74	5,475	30,186	27,832	36	579,570	714	59,513	263,793	255,265	285
African American	66,730	89	5,168	26,981	34,484	8	633,827	903	57,108	238,631	337,118	67
Other/unknown	20,108	45	1,026	6,001	13,032	4	182,102	481	11,313	52,309	117,982	17
Use of Nursing Facilities ^c												
Entire year	151	42	109	0	0	0	1,617	427	1,190	0	0	0
Part year	112	19	88	5	0	0	1,062	130	875	57	0	0
None	150,178	147	11,472	63,163	75,348	48	1,392,820	1,541	125,869	554,676	710,365	369
Maintenance Assistance Statu	s											
Cash	78,126	135	9,979	20,789	47,223	0	747,835	1,468	109,631	195,659	441,077	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty related	5,976	7	7	444	5,470	48	45,352	54	60	2,766	42,103	369
Other/unknown	66,339	66	1,683	41,935	22,655	0	602,312	576	18,243	356,308	227,185	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	3,172	1	1	3,095	75	0	23,826	1	1	23,310	514	0
FFS part year, with Rx claims	3,860	5	30	3,746	77	2	42,139	41	331	40,914	829	24
FFS part year, no Rx claims	1,344	3	6	1,269	65	1	13,147	33	52	12,426	633	3
MC all year, with Rx claims	95,328	167	9,679	38,706	46,748	28	974,237	1,806	109,597	375,355	487,209	270
MC all year, no Rx claims	46,737	32	1,953	16,352	28,383	17	342,150	217	17,953	102,728	221,180	72

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories

are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2

MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a NONDUAL BENEFICIARIES, DELAWARE, 2005

	Beneficia Benefit Month	aries and ns in Cell J of				
	Tab	le 1	Included in Ce	ll K of Table 1	Excluded from (Cell K of Table 1
	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months
All	150,441	1,395,499	103,704	1,020,449	0	375,050
Fee-for-service (FFS) all year	3,172	23,826	3,172	23,826	0	0
FFS part year, with Rx claims	3,860	42,139	3,860	15,558	0	26,581
FFS part year, with no Rx claims	1,344	13,147	1,344	6,828	0	6,319
Managed care (MC) all year, with Rx claims	95,328	974,237	95,328	974,237	0	0
MC all year, with no Rx claims	46,737	342,150	0	0	0	342,150

Source: Data for this table are from the MAX 2005 file for Delaware, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.